IN2012DN00907A - - Google Patents

Info

Publication number
IN2012DN00907A
IN2012DN00907A IN907DEN2012A IN2012DN00907A IN 2012DN00907 A IN2012DN00907 A IN 2012DN00907A IN 907DEN2012 A IN907DEN2012 A IN 907DEN2012A IN 2012DN00907 A IN2012DN00907 A IN 2012DN00907A
Authority
IN
India
Prior art keywords
protein
adamts13
methods
sample
cation exchange
Prior art date
Application number
Inventor
Hasslacher Meinhard
Mitterer Artur
Fiedler Christian
Mayer Christa
Original Assignee
Baxter Healthcare Sa
Baxter Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Baxter Healthcare Sa, Baxter Int filed Critical Baxter Healthcare Sa
Publication of IN2012DN00907A publication Critical patent/IN2012DN00907A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6489—Metalloendopeptidases (3.4.24)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/18—Ion-exchange chromatography
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/34—Extraction; Separation; Purification by filtration, ultrafiltration or reverse osmosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12M—APPARATUS FOR ENZYMOLOGY OR MICROBIOLOGY; APPARATUS FOR CULTURING MICROORGANISMS FOR PRODUCING BIOMASS, FOR GROWING CELLS OR FOR OBTAINING FERMENTATION OR METABOLIC PRODUCTS, i.e. BIOREACTORS OR FERMENTERS
    • C12M47/00—Means for after-treatment of the produced biomass or of the fermentation or metabolic products, e.g. storage of biomass
    • C12M47/12—Purification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N11/00—Carrier-bound or immobilised enzymes; Carrier-bound or immobilised microbial cells; Preparation thereof
    • C12N11/14—Enzymes or microbial cells immobilised on or in an inorganic carrier
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C12N7/04—Inactivation or attenuation; Producing viral sub-units
    • C12N7/06—Inactivation or attenuation by chemical treatment
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/24—Metalloendopeptidases (3.4.24)
    • C12Y304/24087—ADAMTS13 endopeptidase (3.4.24.87)

Abstract

Provided herein are methods for purifying recombinant A Disintegrin-like and Metallopeptidase with Thrombospondin Type 1 Motif 13 (ADAMTS13) protein from a sample. The method comprises enriching for ADAMTS13 protein by chromatographically contacting the sample with hydroxyapatite under conditions that allow ADAMTS13 protein to appear in the eluate or supernatant from the hydroxylapatite. The methods may further comprise tandem chromatography with a mixed mode cation exchange/hydrophobic interaction resin that binds ADAMTS13 protein. Additional optional steps involve ultrafiltration/diafiltration, anion exchange chromatography, cation exchange chromatography, and viral inactivation. Also provided herein are methods for inactivating virus contaminants in protein samples, where the protein is immobilized on a support. Also provided herein are compositions of ADAMTS13 prepared according to said methods.
IN907DEN2012 2009-07-31 2010-08-02 IN2012DN00907A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US23030809P 2009-07-31 2009-07-31
PCT/EP2010/061192 WO2011012726A2 (en) 2009-07-31 2010-08-02 Method for purifying recombinant adamts13 and other proteins and compositions thereof

Publications (1)

Publication Number Publication Date
IN2012DN00907A true IN2012DN00907A (en) 2015-04-03

Family

ID=42588355

Family Applications (1)

Application Number Title Priority Date Filing Date
IN907DEN2012 IN2012DN00907A (en) 2009-07-31 2010-08-02

Country Status (23)

Country Link
US (3) US8945895B2 (en)
EP (3) EP3211077A1 (en)
JP (6) JP5907869B2 (en)
KR (7) KR20230170815A (en)
CN (3) CN107988192A (en)
AU (1) AU2010277491B2 (en)
BR (1) BR112012002140A2 (en)
CA (2) CA2916508A1 (en)
CO (1) CO6612194A2 (en)
DK (1) DK2459715T3 (en)
EA (3) EA034292B1 (en)
ES (1) ES2763207T3 (en)
HR (1) HRP20192303T1 (en)
HU (1) HUE046909T2 (en)
IN (1) IN2012DN00907A (en)
LT (1) LT2459715T (en)
MX (2) MX348178B (en)
NZ (2) NZ620988A (en)
PL (1) PL2459715T3 (en)
PT (1) PT2459715T (en)
SG (2) SG193855A1 (en)
SI (1) SI2459715T1 (en)
WO (1) WO2011012726A2 (en)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2683977C (en) 2007-03-14 2017-04-25 Ligocyte Pharmaceuticals, Inc. A method of norovirus virus-like particle purification comprising ion exchange chromatography
FR2918375B1 (en) * 2007-07-05 2009-10-16 Lab Francais Du Fractionnement USE OF A CHROMATOGRAPHY MEDIUM TO REDUCE THE QUANTITY OF ADAMTS13 IN A PLASMA-DERIVED SOLUTION
CN103917655B (en) * 2011-03-14 2016-05-25 康泰伦特药物解决方案有限责任公司 Decorin composition and use thereof
WO2012149197A2 (en) 2011-04-27 2012-11-01 Abbott Laboratories Methods for controlling the galactosylation profile of recombinantly-expressed proteins
US9096648B2 (en) * 2011-08-19 2015-08-04 Emd Millipore Corporation Methods of reducing level of one or more impurities in a sample during protein purification
US9181572B2 (en) 2012-04-20 2015-11-10 Abbvie, Inc. Methods to modulate lysine variant distribution
US9067990B2 (en) 2013-03-14 2015-06-30 Abbvie, Inc. Protein purification using displacement chromatography
WO2013158279A1 (en) 2012-04-20 2013-10-24 Abbvie Inc. Protein purification methods to reduce acidic species
WO2013176754A1 (en) 2012-05-24 2013-11-28 Abbvie Inc. Novel purification of antibodies using hydrophobic interaction chromatography
IN2014DN10441A (en) * 2012-06-21 2015-08-21 Baxter Int
JOP20130186B1 (en) * 2012-06-22 2021-08-17 Takeda Vaccines Montana Inc Purification of virus like particles
US9512214B2 (en) 2012-09-02 2016-12-06 Abbvie, Inc. Methods to control protein heterogeneity
SG11201504249XA (en) 2012-09-02 2015-07-30 Abbvie Inc Methods to control protein heterogeneity
BR112015015948B1 (en) * 2013-01-09 2022-05-17 Takeda Pharmaceutical Company Limited METHOD OF PURIFICATION OF RECOMBINANT ARYLSULPHATASE A (ASA) PROTEIN
EP2830651A4 (en) 2013-03-12 2015-09-02 Abbvie Inc Human antibodies that bind human tnf-alpha and methods of preparing the same
WO2014151878A2 (en) 2013-03-14 2014-09-25 Abbvie Inc. Methods for modulating protein glycosylation profiles of recombinant protein therapeutics using monosaccharides and oligosacharides
US8921526B2 (en) 2013-03-14 2014-12-30 Abbvie, Inc. Mutated anti-TNFα antibodies and methods of their use
US9017687B1 (en) 2013-10-18 2015-04-28 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same using displacement chromatography
WO2015051293A2 (en) 2013-10-04 2015-04-09 Abbvie, Inc. Use of metal ions for modulation of protein glycosylation profiles of recombinant proteins
US9085618B2 (en) 2013-10-18 2015-07-21 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same
US8946395B1 (en) * 2013-10-18 2015-02-03 Abbvie Inc. Purification of proteins using hydrophobic interaction chromatography
US9181337B2 (en) 2013-10-18 2015-11-10 Abbvie, Inc. Modulated lysine variant species compositions and methods for producing and using the same
US20150139988A1 (en) 2013-11-15 2015-05-21 Abbvie, Inc. Glycoengineered binding protein compositions
US8859252B1 (en) 2014-01-02 2014-10-14 Aerial Biopharma, Llc Prostatic acid phosphatase, compositions comprising the same, and methods for producing and/or purifying the same
JP6609561B2 (en) * 2014-02-04 2019-11-20 バイオジェン・エムエイ・インコーポレイテッド Use of cation exchange chromatography in flow-through mode to enrich post-translational modifications
WO2018027169A1 (en) 2016-08-04 2018-02-08 Baxalta Incorporated Use of adamts13 for treating, ameliorating and/or preventing vaso-occlusive crisis in sickle cell disease, acute lung injury and/or acute respiratory distress syndrome
CN112105430A (en) * 2018-04-03 2020-12-18 默克专利股份有限公司 Low salt elution of target proteins in CEX chromatography media and biopharmaceutical feedstocks
KR102140531B1 (en) * 2018-08-07 2020-08-04 (주)휴온스 The processing method of Gly-Tβ4
AU2020253381A1 (en) * 2019-04-03 2021-12-02 Genzyme Corporation Continuous production of recombinant proteins
WO2023052556A1 (en) * 2021-09-30 2023-04-06 Ichnos Sciences SA Methods of inactivating viral contaminants with a mixture of solvent and detergent
TW202342522A (en) 2022-03-07 2023-11-01 日商武田藥品工業股份有限公司 Affinity chromatographic production of clinical human igg products
KR20230159284A (en) * 2022-05-10 2023-11-21 주식회사 녹십자 A Novel Liquid Formulation for Plasma Protein
WO2023219379A1 (en) * 2022-05-10 2023-11-16 주식회사 녹십자 Novel liquid formulation for lyophilization of plasma protein

Family Cites Families (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4239854A (en) * 1978-04-24 1980-12-16 Sumitomo Chemical Company, Limited Enzyme-immobilization carriers and preparation thereof
US4540573A (en) 1983-07-14 1985-09-10 New York Blood Center, Inc. Undenatured virus-free biologically active protein derivatives
US5283182A (en) * 1986-09-17 1994-02-01 Beecham Group Plc Preparation of immobilized hydantoinase stabilized with divalent metal ions
CA1339946C (en) 1987-03-31 1998-07-07 Michael J. Griffith Ultrapurification process for polypeptides
US5792835A (en) * 1991-09-05 1998-08-11 Baxter International Inc. Method of preparing a topical fibrinogen complex
FR2681867B1 (en) 1991-09-26 1993-12-31 Pasteur Merieux Serums Vaccins FACTOR VIII PURIFICATION PROCESS AND PREPARATIONS OBTAINED.
FR2686899B1 (en) * 1992-01-31 1995-09-01 Rhone Poulenc Rorer Sa NOVEL BIOLOGICALLY ACTIVE POLYPEPTIDES, THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM.
ATE194921T1 (en) 1992-03-02 2000-08-15 Bioeng Inc METHOD FOR INACTIVATION OF VIRUSES
US5296228A (en) * 1992-03-13 1994-03-22 Allergan, Inc. Compositions for controlled delivery of pharmaceutical compounds
US5288853A (en) 1992-04-30 1994-02-22 Alpha Therapeutic Corporation Factor viii purification process
US5578480A (en) * 1993-04-23 1996-11-26 American Cyanamid Company Methods for the isolation and purification of the recombinantly expressed chondroitinase I and II enzymes from P. vulgaris
GB9503750D0 (en) * 1995-02-24 1995-04-12 Common Services Agency Thrombin preparation
US5688912A (en) 1995-09-22 1997-11-18 Bayer Corporation Peptide ligands which bind to von willebrand factor
US5831003A (en) 1996-06-28 1998-11-03 Bayer Corporation Peptides which bind to prothrombin and thrombin
US5786458A (en) * 1996-06-28 1998-07-28 Bayer Corporation Selective stabilization of protein during viral inactivation
US7141393B2 (en) * 1996-12-26 2006-11-28 Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo Interleukin-18-receptor proteins
US6429192B1 (en) 1998-06-10 2002-08-06 Statens Serum Institut Purification process for production of mannan-binding lectin and an MBL medicinal product
US6251860B1 (en) * 1998-07-07 2001-06-26 Suomen Punainen Risti Veripalvelu Pharmaceutical preparations
US6214221B1 (en) 1999-02-22 2001-04-10 Henry B. Kopf Method and apparatus for purification of biological substances
US6451978B2 (en) * 2000-01-21 2002-09-17 Biovitrum Ab Purification of antithrombin-III-α and β
IL136552A (en) 2000-06-05 2005-05-17 Omrix Biopharmaceuticals Ltd Method for the inactivation of viruses by a solvent - detergent combination and by nanofiltration
WO2002031163A1 (en) * 2000-10-11 2002-04-18 Kazusa Dna Research Institute Foundation Novel adamts family polypeptide and gene encoding the same
US6926894B2 (en) 2000-11-22 2005-08-09 Baxter Aktiengesellschaft Composition exhibiting a von willebrand factor (vWF) protease activity comprising a polypeptide chain with the amino acid sequence AAGGILHLELLV
CN1230526C (en) * 2001-02-27 2005-12-07 成都夸常科技有限公司 Method for removing organic solvent used as virus inactivator and/or detergent
AU2002336367A1 (en) 2001-08-16 2003-03-03 The Regents Of The University Of Michigan Adamts13 genes and proteins and variants, and uses thereof
JP2003144154A (en) * 2001-11-14 2003-05-20 Mitsubishi Pharma Corp New adamts family polypeptide and gene encoding the same
IL158297A0 (en) * 2001-12-05 2004-05-12 Cangene Corp Pharmaceutical compositions containing immune globulin and methods for the preparation thereof
AU2002359816B2 (en) 2001-12-21 2006-07-13 Immunex Corporation Methods for purifying protein
US20030133829A1 (en) 2001-12-21 2003-07-17 Baxter Healthcare Corporation Process for inactivating pathogens in a biological material
GB0216002D0 (en) * 2002-07-10 2002-08-21 Nat Blood Authority Process and composition
GB0216001D0 (en) 2002-07-10 2002-08-21 Nat Blood Authority Process and composition
WO2004035778A1 (en) * 2002-10-18 2004-04-29 Japan As Represented By The President Of National Cardiovascular Center Substrates specific to von willebrand factor cleaving protease and method of assaying the activity
CA2487673C (en) * 2003-12-02 2010-11-02 F. Hoffmann-La Roche Ag Improved method for the recombinant production and purification of protein kinases
GB0405330D0 (en) * 2004-03-10 2004-04-21 Astrazeneca Ab Enzyme and preparation method
US20080138790A1 (en) * 2004-04-13 2008-06-12 Winslow Robert M Methods and Compositions for Simultaneously Isolating Hemoglobin from Red Blood Cells and Inactivating Viruses
US9624260B2 (en) 2004-06-07 2017-04-18 Therapure Biopharma Inc. Process for isolation of plasma or serum proteins
US7270976B2 (en) 2004-07-19 2007-09-18 American Diagnostica, Inc. Methods for measuring ADAMTS13 activity and protein on platelets and in plasma
DE102004044419B4 (en) * 2004-09-14 2010-04-15 Biotest Ag Process for the purification of a von Willebrand factor by means of hydroxylapatite continuous chromatography
EP1838333A1 (en) * 2005-01-05 2007-10-03 Foundation For Fatal Rare Disease Pharmaceutically active antiviral peptides
US20060193966A1 (en) * 2005-02-28 2006-08-31 Shaowen Wu Multi-anion treated soy proteins and methods for preparation thereof
EP1902141B1 (en) 2005-06-17 2012-02-08 Baxter International Inc. Adamts13-comprising compositions having thrombolytic activity
FR2887883B1 (en) 2005-06-29 2007-08-31 Lab Francais Du Fractionnement PROCESS FOR SEPARATING FIBRINOGEN PROTEINS, FACTOR XIII AND BIOLOGICAL GLUE OF SOLUBILIZED PLASMA FRONTION AND PREPARATION OF LYOPHILIZED CONCENTRATES OF SAID PROTEINS
JP2009518345A (en) * 2005-12-07 2009-05-07 テフニーシェ ウニヴェルジテート ミュンヘン Affinity ligands of small peptides and peptidomimetics for factor VIII and factor VIII-like proteins
JP5067917B2 (en) 2005-12-28 2012-11-07 アルフレッサファーマ株式会社 Separation and purification method of ADAMTS13
CN101384728B (en) 2006-02-16 2013-05-22 三菱化学美迪恩斯株式会社 Method for detecting condition of a patient in consciousness disorder and kit for detection
US7468258B2 (en) 2006-03-07 2008-12-23 Wake Forest University Health Sciences Self-quenching homofluorophore compositions for detecting enzyme activity
WO2008057074A1 (en) * 2006-11-06 2008-05-15 Millipore Corporation Method of flow-through chromatography
US8669045B2 (en) 2007-02-13 2014-03-11 Ajinomoto Co., Inc. Method for inactivating viruses with slightly acidic arginine
US8685665B2 (en) 2007-06-22 2014-04-01 The Chemo-Sero-Therapeutic Research Institute ADAMTS-13 mutant
FR2918375B1 (en) * 2007-07-05 2009-10-16 Lab Francais Du Fractionnement USE OF A CHROMATOGRAPHY MEDIUM TO REDUCE THE QUANTITY OF ADAMTS13 IN A PLASMA-DERIVED SOLUTION
AU2008274195B2 (en) 2007-07-11 2013-09-05 Novo Nordisk A/S Purification of factor VIII using a mixed-mode or multimodal resin
US20110097318A1 (en) * 2007-08-31 2011-04-28 Amgen Inc. Solid-State Protein Formulation
US20090130714A1 (en) * 2007-09-24 2009-05-21 Reliance Life Sciences Pvt.Ltd. Process for purifying recombinanat tissue plasminogen activator (TPA)

Also Published As

Publication number Publication date
EA201992487A1 (en) 2020-05-31
JP2015147815A (en) 2015-08-20
MX348178B (en) 2017-05-29
AU2010277491B2 (en) 2015-12-17
JP2021004265A (en) 2021-01-14
CA2769362A1 (en) 2011-02-03
KR20170096061A (en) 2017-08-23
JP5907869B2 (en) 2016-04-26
CN102482660A (en) 2012-05-30
NZ597756A (en) 2014-03-28
US20150104849A1 (en) 2015-04-16
JP2013500711A (en) 2013-01-10
NZ620988A (en) 2015-07-31
AU2010277491A2 (en) 2012-06-21
JP2016222724A (en) 2016-12-28
PL2459715T3 (en) 2020-04-30
WO2011012726A2 (en) 2011-02-03
KR101883610B1 (en) 2018-07-30
KR20120053013A (en) 2012-05-24
EP2459715B1 (en) 2019-10-02
KR20190122272A (en) 2019-10-29
KR20200146042A (en) 2020-12-31
KR101769634B1 (en) 2017-08-18
SG178175A1 (en) 2012-03-29
DK2459715T3 (en) 2020-01-06
KR20220066435A (en) 2022-05-24
US20110081700A1 (en) 2011-04-07
KR20230170815A (en) 2023-12-19
EP4299735A2 (en) 2024-01-03
AU2010277491A1 (en) 2012-02-16
JP6216930B2 (en) 2017-10-25
CN107267490A (en) 2017-10-20
CN107988192A (en) 2018-05-04
MX2012001263A (en) 2012-05-22
PT2459715T (en) 2020-01-09
CA2916508A1 (en) 2011-02-03
US8945895B2 (en) 2015-02-03
EA034292B1 (en) 2020-01-24
CO6612194A2 (en) 2013-02-01
HUE046909T2 (en) 2020-04-28
EP4299735A3 (en) 2024-04-24
JP2018203781A (en) 2018-12-27
EP2459715A2 (en) 2012-06-06
SI2459715T1 (en) 2020-01-31
WO2011012726A3 (en) 2011-03-31
SG193855A1 (en) 2013-10-30
ES2763207T3 (en) 2020-05-27
EA023783B1 (en) 2016-07-29
EA201500952A1 (en) 2016-05-31
EP3211077A1 (en) 2017-08-30
KR20180087463A (en) 2018-08-01
BR112012002140A2 (en) 2015-09-15
HRP20192303T1 (en) 2020-10-02
US20230242897A1 (en) 2023-08-03
US11661593B2 (en) 2023-05-30
JP2022171925A (en) 2022-11-11
LT2459715T (en) 2020-01-10
EA201270214A1 (en) 2012-08-30

Similar Documents

Publication Publication Date Title
IN2012DN00907A (en)
MX2018014395A (en) Isolation and purification of antibodies using protein a affinity chromatography.
MX341136B (en) Isolation and purification of anti-il-13 antibodies using protein a affinity chromatography.
PH12020500027A1 (en) Purification of iduronate-2-sulfatase
JP2013500711A5 (en)
MX2007003906A (en) Methods and compositions for improving recombinant protein production.
MX2015008875A (en) Methods for purification of arylsulfatase a.
SG157346A1 (en) Improved purification of collagenases from clostridium histolyticum liquid culture
WO2010048192A3 (en) Viral inactivation during purification of antibodies
WO2008085962A3 (en) Cell culture methods for producing recombinant proteins in the presence of reduced levels of one or more contaminants
MX2011011454A (en) Plants having enhanced yield-related traits and a method for making the same.
WO2011097381A3 (en) Engineered enzymes with methionine-gamma-lyase enzymes and pharmacological preparations therof
WO2006113475A3 (en) Methods and compositions to modulate adhesion and stress tolerance in bacteria
WO2006091535A3 (en) Novel egg receptors for sperm proteins
BRPI1013956B8 (en) method for isolating a recombinant protein, spray dried particles, composition, and use of spray dried particles
MX2022001166A (en) Method for viral inactivation.
EP1870454A4 (en) Method for producing dipeptide
ATE553194T1 (en) METHOD FOR PRODUCING DIPEPTIDE
WO2019067743A8 (en) Enzyme compositions with reduced viral and microbial contamination
AU2003277694A1 (en) Porcine uroplakin ii promoter and the production method of useful proteins using said promoter
WO2022133191A3 (en) Protein compositions and methods for producing and using the same